Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TA-CD: Phase II data

An open-label U.S. Phase II trial in 13 patients showed that

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE